BDR Blonder Tongue Laboratories Inc

On December 9, 2020, Blonder Tongue Laboratories, Inc. (the “Company”) received notification (the “December Notice”) from NYSE American LLC (“NYSE American”) that the Company is not in compliance with the continued listing standard set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”). That section applies if the reported stockholders’ equity of the listed company is less than $4 million and the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The December Notice indicated that the Company reported stockholders’ equity of $2,614,000 as of September 30, 2020 and reported losses from continuing operations and/or net losses in each of its five most recent fiscal years ended December 31, 2019, resulting in the Company failing to comply with the continued listing standard. As a result, the Company is subject to the procedures and requirements of Section 1009 of the Company Guide, in respect of which the Company first became subject, as set forth in the June Notice described below.

As previously reported, on June 10, 2020 the Company received written notification (the “June Notice”) from NYSE American that the Company is not in compliance with the continued listing standard under Section 1003(a)(iii) of the Company Guide, which requires a listed company to have stockholders’ equity of at least $6 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The June Notice indicated that the Company reported stockholders’ equity of $5.4 million as of March 31, 2020 and reported losses from continuing operations and/or net losses in each of its five most recent fiscal years ended December 31, 2019, resulting in the Company failing to comply with the continued listing standard. In response to the June Notice, the Company submitted a plan to regain compliance and on August 27, 2020, the Company received notice that its plan had been accepted and that the Company had been granted a plan period through December 10, 2021 to regain compliance with Section 1003(a)(iii) of the Company Guide. The December 10, 2021 deadline will also apply to the noncompliance noted in the December Notice. As a result, the Company must be in compliance with Section 1003(a)(ii) and Section 1003(a)(iii) by that deadline.

During the plan period the Company will be subject to periodic review by NYSE Regulation staff, including quarterly monitoring, to determine if the Company is making progress consistent with the plan. If the Company is not in compliance with the continued listing standards by December 10, 2021, or if NYSE Regulation determines that the Company is not making sufficient progress consistent with the plan, delisting proceedings will be instituted against the Company, as appropriate.

As disclosed in the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2020, due largely to the continuing effects of the COVID-19 pandemic, the Company did not meet certain elements of the near-term milestones included as part of the compliance plan. It is possible that NYSE Regulation will determine that the Company is not making sufficient progress consistent with its compliance plan and, as a result, may initiate delisting proceedings. Although NYSE American has not yet asked the Company to submit a new or amended plan, the Company has provided NYSE American with an updated plan. The Company cannot provide assurance that it will make sufficient progress to regain compliance with the listing standards by December 10, 2021, that the Company's updated compliance plan will be accepted without additional conditions being imposed, or at all, or that delisting proceedings may not be instituted based on the Company not meeting certain elements of its original compliance plan or any future failure to meet its updated compliance plan. If delisting proceedings are instituted, the Company would have the right to appeal any delisting determination.

A copy of the Company’s press release dated December 10, 2020 regarding the December Notice from NYSE American is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.